AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin.

Toronto-based NoNO Inc. announced results from the pivotal Phase III ESCAPE-NA1 trial of intravenous nerinetide in patients with acute ischemic stroke who were chosen to undergo endovascular thrombectomy.

On Valentine’s Day, BioSpace would be remiss not to mention, er, matters of the heart. There are reportedly 59 life sciences companies or organizations worldwide that focus on the cardiovascular system, ranging from the Aab Cardiovascular Research Institute based in West Henrietta, New York to XyloCor Therapeutics, with headquarters in Philadelphia. That number is probably low.

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection in individuals at increased risk of stroke.

Few nutritional supplements can protect people from developing or dying from cardiovascular disease, and some may actually be harmful, a research review suggests.

Yale University scientists succeeded in restoring basic cellular activity in pigs’ brains hours after their deaths in a finding that may one day lead to advances in treating human stroke and brain injuries, researchers reported.

Blood pressure and stroke risk rise steadily the more alcohol people drink, and previous claims that one or two drinks a day might protect against stroke are not true, according to a genetic study.

The Nasdaq indicated that there was a record amount of biotech initial public offerings (IPOs) in 2018, totaling around $8.2 billion raised, breaking 2014’s record of $6.5 billion.

Adults who sleep too little or too much may have an increased risk of heart attack or stroke, say researchers who argue that the best way to think of the harmful effect is in terms of “excess heart age.”

U.S. health regulators approved Amicus Therapeutics’ Galafold as the first oral therapy to treat Fabry disease, a rare and sometimes fatal condition.